
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Allogeneic Cell Therapy Manufacturing Market Snapshot
Chapter 4. Global Allogeneic Cell Therapy Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Allogeneic Cell Therapy Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Induced pluripotent stem cells (iPSC)
5.2.2. T-cells and Natural killer (NK) cells
5.2.3. Human pluripotent stem cells (hPSCs)
5.2.4. Mesenchymal stem cells (MSC)
5.2.5. β-cells
5.2.6. Neurons
5.2.7. Immortalized and engineered cell lines
5.2.8. Tissue engineered product
Chapter 6. Market Segmentation 2: By Scale of Operation Estimates & Trend Analysis
6.1. By Scale of Operation & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operation
6.2.1. Preclinical Scale Operations
6.2.2. Clinical Scale Operations
6.2.3. Commercial Scale Operations
Chapter 7. Allogeneic Cell Therapy Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
7.1.3. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.2. Europe
7.2.1. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
7.2.3. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
7.3.3. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
7.4.2. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
7.4.3. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
7.5.2. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
7.5.3. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Lonza Group
8.2.2. KBI Biopharma, Inc.
8.2.3. Waisman Biomanufacturing
8.2.4. Cell and Gene Therapy Catapult
8.2.5. Thermo Fisher Scientific, Inc.
8.2.6. Merck KGaA
8.2.7. Catalent Inc.
8.2.8. Lonza Group
8.2.9. Oxford Biomedica Plc
8.2.10. Fujifilm Cellular Dynamics, Inc.
8.2.11. Wuxi Apptec
8.2.12. Charles River Laboratories International, Inc.
8.2.13. The Discovery Labs LLC
8.2.14. ABL, Inc.
8.2.15. BioCentriq
8.2.16. Commercializing Living Therapies
8.2.17. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.